Since last year, a high-dose influenza vaccine has been available in Switzerland in addition to the standard vaccines, which is recommended and approved for people over 75 and for people aged 65 and over with an additional risk factor. Empirical data confirm the higher efficacy of quadrivalent high-dose compared to quadrivalent standard-dose influenza vaccines in these age groups.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Esophageal Cancer
A Comparison of Endoscopic and Surgical Innovations
- PMR and LVV: Current EULAR Recommendations
Polymyalgia rheumatica, giant cell arteritis, and Takayasu arteritis
- Psychedelic-assisted therapy
Current status of PAT
- First-line treatment for T2D
SGLT2i, metformin, or both?
- Biophilic Design of Work Environments
Effects on Health, Well-Being, and Productivity
- From symptom to diagnosis
Intrapelvic mass with an ambiguous differential diagnosis
- Endocrinology: APECED-Associated Hypoparathyroidism
A parathyroid hormone analog corrected serum calcium levels
- Transient ischemic attack